McKesson(MCK)

Leader

Largest US pharmaceutical distributor with $308.9B FY2024 revenue; thin-margin distribution triopoly with Cencora and Cardinal Health; US Oncology Network (1,700+ oncologists) is highest-margin segment.

Updated March 2026

Company Overview

About McKesson

McKesson Corporation is the largest pharmaceutical distributor in North America and a leading healthcare services company, founded in 1833 in New York City by John McKesson and Charles Olcott and now headquartered in Irving, Texas, trading on NYSE (MCK). The company reported approximately $308.9 billion in revenues for fiscal year 2024 (ending March 31, 2024) under CEO Brian Tyler, making it one of the highest-revenue companies in the United States—though the vast majority of revenues represent pass-through pharmaceutical product costs distributed to approximately 40,000 pharmacies, health systems, and medical providers across North America. McKesson operates through four segments: U.S. Pharmaceutical (the dominant distribution engine), Prescription Technology Solutions (pharmacy benefits technology including CoverMyMeds e-prior authorization), Medical-Surgical Solutions (physician office and extended care medical supply distribution), and International (primarily Canadian distribution through McKesson Canada).

Business Model & Competitive Advantage

McKesson's pharmaceutical distribution business generates thin but highly predictable gross margins—typically 2-4% of revenues—on the enormous volume of branded and generic pharmaceuticals flowing from manufacturers to dispensing points. The company earns fee-for-service and price appreciation income in addition to distribution margin, particularly from branded pharmaceuticals where manufacturer price increases translate into inventory holding gains. The specialty pharmaceutical distribution segment—particularly oncology drugs distributed through McKesson's US Oncology Network (a physician services organization supporting over 1,700 oncologists)—commands higher margins than standard pharmaceutical distribution and provides access to high-cost specialty drugs that require specialized handling, reimbursement support, and clinical expertise.

Competitive Landscape 2025–2026

In 2025-2026, McKesson competes with Cencora (formerly AmerisourceBergen, ABC) and Cardinal Health (CAH) in the pharmaceutical distribution triopoly that collectively handles approximately 90% of U.S. pharmaceutical distribution. This oligopolistic structure provides pricing stability and durable margins absent competitive disruption. The three distributors' partial responsibility (as wholesalers) for the U.S. opioid epidemic resulted in a combined $21 billion settlement in 2022—McKesson's share approximately $8.2 billion payable over 18 years—creating a significant financial obligation that is being funded from ongoing free cash flow. McKesson's increasing focus on oncology—through US Oncology Network expansion, specialty drug distribution growth, and oncology software platforms—addresses the highest-growth and highest-margin segment within pharmaceutical distribution.

Founded
1833
Headquarters
Manhattan, New York
Revenue
$308900M
Curated content • Fact-checked and verified

The McKesson Story

Founded in 1833
Manhattan, New York
Founded by John McKesson, Charles Olcott

Founders

John McKessonCharles Olcott
Loading News...

Company Timeline

Major milestones in McKesson's journey

16
Total Events
0
Funding Rounds
7
Acquisitions
1
Product Launches
Loading Culture...

Leadership Team

Meet the leaders behind McKesson

Brian S. Tyler, Ph.D.

Chief Executive Officer & Board Member

Brian Tyler has served as CEO of McKesson Corporation since April 2019 and previously served as President and Chief Operating Officer from August 2018 to March 2019. With more than 25 years at McKesson, Tyler has held wide-ranging leadership roles across McKesson Europe, North American Pharmaceutical Distribution Services, Corporate Strategy and Business Development, and other divisions, bringing comprehensive company knowledge and strategic vision to the CEO role.

Leann Smith

Executive Vice President & Chief Human Resources Officer

Leann Smith leads McKesson's global human resources strategy, overseeing talent acquisition, employee development, compensation and benefits, diversity and inclusion initiatives, and organizational culture across the company's 80,000+ employee base spanning North America and international operations.

Tom Rodgers

Executive Vice President & Chief Strategy and Business Development Officer

Tom Rodgers is responsible for McKesson's corporate strategy development, mergers and acquisitions execution, strategic partnerships, and long-term business planning. He has played a key role in major strategic transactions including the Core Ventures, PRISM Vision Holdings, and Compile acquisitions that have strengthened McKesson's specialty healthcare platform.

Dr. Kelvin Baggett

Chief Impact Officer

Dr. Kelvin Baggett leads McKesson's global strategy and execution of environmental, social, and governance (ESG) positions, sustainability and environmental practices, diversity, equity and inclusion (DEI) initiatives, McKesson Foundation philanthropy, and corporate social responsibility programs, positioning the company as a responsible corporate citizen.

Open Positions

Reddit Discussions

Loading Competitive Intelligence...

Key Differentiators

Market Leader

McKesson is recognized as a market leader in the Healthcare sector, demonstrating strong industry presence and customer trust.

Enterprise Scale

With $308900M in revenue, McKesson operates at enterprise scale with proven market validation.

Frequently Asked Questions

Not So Random Others

Yoneda Labs

Healthcare
HealthtechB2bNorth America

Yoneda Labs is a San Francisco-based AI company applying foundation models to automate chemical reaction optimization for drug discovery and pharmaceutical process development — providing chemists wit

Decoda Health

Healthcare
HealthtechAi PoweredAutomationNorth America

Decoda Health is a San Francisco-based AI healthcare administration platform — backed by Y Combinator (S23) with $4.5 million raised from YC, Amino Capital, Bossa Nova Ventures, Cadenza Ventures, Grap

Fortuna Health

Healthcare
HealthtechB2bAi PoweredAutomationNorth America

Fortuna Health is a New York City-based healthcare technology company — backed by Y Combinator with $22 million in total funding including an $18 million Series A in July 2025 led by Andreessen Horowi

Brisk

Consumer Food & Beverage
B2cManufacturingNorth AmericaFortune500

Brisk is a functional beverage brand offering ready-to-drink iced tea and juice drinks, jointly owned by PepsiCo and Unilever under the Lipton brand partnership. Launched in the 1990s, Brisk positione

Altria

Consumer Goods
B2cManufacturingNorth AmericaPublicFortune500

Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and s

AbbVie

Healthcare
AnalyticsB2bEnterpriseGlobalHealthtechPublic

AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Sp

Compare McKesson with Competitors

Side-by-side AI visibility scores, platform breakdown, and market position.

For McKesson

Claim This Profile

Are you from McKesson? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.

Claim McKesson Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention McKesson vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →